Meeting
2020 ASCO Virtual Scientific Program
Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.
Presenter
Yuqin Song, MD
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), the Department of Lymphoma, Peking University Cancer Hospital & Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03655483
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8033)
DOI
10.1200/JCO.2020.38.15_suppl.8033
Abstract #
8033
Poster Bd #
366
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2015 ASCO Annual Meeting
Changing Expectations for Leadership Positions in Academic Medicine: Opportunities and Challenges for Educators
Speaker: David H. Johnson, MD
Speaker: Panel Discussion
Speaker: Eric P. Winer, MD
Videos & Slides
2024 ASCO Annual Meeting
Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity.
Speaker: Wei Meng, MD